Abion announced on the 19th that it will present the preclinical results of the combination therapy of Vabametkib (ABN401) and Lazertinib, as well as the development strategies for ABN501 and ABN202, at the American Association for Cancer Research (AACR). The event will be held from the 25th to the 30th of next month (local time) in Chicago, Illinois, USA.
The company previously confirmed strong antitumor efficacy by recording a tumor growth inhibition (TGI) rate of 96.6% through combination treatment in patient-derived xenograft (PDX) models with EGFR mutations. This demonstrated that the therapy could be an effective anticancer treatment strategy. At AACR 2025, the latest research results on the combination therapy, including drug-drug interaction (DDI) studies between Vabametkib and Lazertinib, will be presented.
The combination of the two drugs showed a low possibility of interaction, indicating that they do not inhibit each other's drug effects. This suggests that Vabametkib can maximize its efficacy when combined with Lazertinib and can be used safely without drug interference.
A company representative stated, “The combination therapy of Vabametkib and Lazertinib could offer new hope for lung cancer patients with MET amplification and EGFR mutations,” adding, “Since we have received approval for changes to the Phase 2 clinical trial plan from the U.S. Food and Drug Administration (FDA) and the Korean Ministry of Food and Drug Safety, we will rapidly proceed with clinical development to provide more effective and innovative treatment options.”
Abion will also introduce the development strategies for ABN501 and ABN202. ABN501 is a claudin-3 (CLDN3) targeted antibody therapy, and the company will present its high safety profile confirmed in monkey and rat models, as well as its effective anticancer effects in preclinical models.
BsABN501 (anti-CLDN3xCD3 T cell engager) simultaneously targets CLDN3 and CD3 to activate T cells and effectively eliminate CLDN3-expressing cancer cells. Research results confirmed that BsABN501 induces strong cytotoxicity and significantly reduces tumor size in animal models.
The company also plans to present the preclinical research outcomes of ABN202, an antibody-cytokine conjugate platform targeting TROP2. In particular, by demonstrating superior efficacy compared to existing antibody-drug conjugates (ADCs) in ADC-resistant and low-antigen-expression models, the company aims to propose a ‘Beyond ADC’ development strategy that overcomes current limitations.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
